Topological Analysis of the baseline characteristics of relapsed and/or refractory multiple myeloma (R/R MM) patients treated with carfilzomib in clinical trials to identify cohorts that represent levels of risk of select cardiovascular adverse events (CV AEs) in that patient population (20190506)

01/05/2020
21/10/2021
EU PAS number:
EUPAS35042
Study
Finalised
Documents
Study protocol
Initial protocol
English (1.98 MB - PDF) View document
Study results
Study results
English (1.19 MB - PDF) View document
Study report
Other information